MNG1008
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- TGF_BETA_SIGNALING+0.167
- ALLOGRAFT_REJECTION+0.162
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.159
- PROTEIN_SECRETION+0.111
- PI3K_AKT_MTOR_SIGNALING+0.101
- XENOBIOTIC_METABOLISM+0.098
- IL6_JAK_STAT3_SIGNALING+0.083
- P53_PATHWAY+0.074
- FATTY_ACID_METABOLISM+0.071
- BILE_ACID_METABOLISM+0.043
Top 10 suppressed
- ANGIOGENESIS-0.435
- E2F_TARGETS-0.424
- MYC_TARGETS_V2-0.398
- G2M_CHECKPOINT-0.395
- MYC_TARGETS_V1-0.348
- INTERFERON_ALPHA_RESPONSE-0.340
- APICAL_SURFACE-0.284
- OXIDATIVE_PHOSPHORYLATION-0.206
- UNFOLDED_PROTEIN_RESPONSE-0.204
- MTORC1_SIGNALING-0.200
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-05-4384-01A-01R-1755-07 | — | cohortA2 | 0.778 |
| 2 | TCGA-55-8206-01A-11R-2241-07 | — | cohortA1 | 0.765 |
| 3 | AUR-AFE4-TTM1-A-1-1-R-A742-41 | — | A | 0.763 |
| 4 | C3L-02350 | — | cohortA1 | 0.753 |
| 5 | SRR1313099 | — | A | 0.748 |
| 6 | TCGA-86-8056-01A-11R-2241-07 | — | cohortA1 | 0.745 |
| 7 | TCGA-44-5645-01A-01R-1628-07 | — | cohortA1 | 0.740 |
| 8 | MBCProject_5856_T0B_RNA | — | A | 0.728 |
| 9 | C3N-02721 | — | cohortA1 | 0.724 |
| 10 | TCGA-67-6217-01A-11R-1755-07 | — | cohortA1 | 0.722 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| TGF_BETA_SIGNALING | 0.167 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.162 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.159 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.111 | Remibrutinib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.101 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.098 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.083 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.074 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.071 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.043 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.040 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.029 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.022 | Temsirolimus | — uncovered |
| MYOGENESIS | 0.007 | Inavolisib | — uncovered |